This roundup explores updated 2024-2025 COVID-19 vaccine effectiveness data, an FDA-cleared 4-pathogen home test, and new evidence on metformin for long COVID risk.
A large pragmatic randomized trial evaluated whether a bivalent respiratory syncytial virus (RSV) prefusion F protein-based vaccine could reduce RSV-related hospitalizations among adults aged 60 years or...
In a nationwide Danish trial of more than 130,000 adults aged 60 years and older, a single dose of the bivalent RSV prefusion F protein vaccine reduced all-cause cardiorespiratory hospitalizations by nearly...
New studies highlight that while persistent SARS-CoV-2 infections can evolve rapidly within individuals, they rarely spread onward. Meanwhile, the 2024–2025 COVID-19 vaccine reduced mortality by 64% among...
In this roundup, experts outline diverging pediatric COVID vaccine recommendations, midlife peaks in long COVID risk, new findings on abnormal uterine bleeding and cycle-related symptoms in long COVID, and...
New multicenter US data show that a single respiratory syncytial virus (RSV) vaccine dose protects against hospitalization in older adults, though effectiveness wanes over time and is lower in...
In a phase 1 trial, a single injection of an mRNA RSV vaccine boosted neutralizing antibody levels in seropositive children and was well tolerated, with no serious adverse events or study discontinuations...
This respiratory disease roundup covers the potential impact of a new COVID-19 variant, changes in funding for pandemic influenza vaccines, and a study on cardiac event risks in respiratory syncytial virus...
